Prophylaxis of influenza A virus infections is based on the vaccines inducing antibodies to the major viral antigens, hemagglutinin (HA) and neuraminidase (NA). Since these antigens continuously change during virus replication in various hosts, only the currently circulating strains should be used in the vaccines. Besides, monitoring of the naturally occurring changes in HA, NA, and respective genes, especially those associated with resistance to the NA inhibitors is necessary. The NA genes of 30 Iranian isolates of influenza H1N1 virus from the seasons 2005-2009 were sequenced and subjected to the sequence and phylogenetic analyses. The seasonal isolates turned out to be closely related to the corresponding vaccine strains, except for the 2007-2008 isolates, which also displayed a higher nucleotide variation. A resistance to the NA inhibitors was found in the 2008-2009 isolates only. The average nucleotide identities of the isolates with corresponding vaccine strains for the years 2005-2009 were 98.83%, 98.55%, 98.7%, 97.55%, and 98.76%, respectively.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4149/av_2010_03_205 | DOI Listing |
Pharmaceutics
December 2024
Phase I Clinical Trial Unit, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Background: A broad-spectrum anti-SARS-CoV-2 monoclonal antibody (mAb), SA55, is highly effective against SARS-CoV-2 variants. This trial aimed at demonstrating the safety, tolerability, local drug retention and neutralizing activity, systemic exposure level, and immunogenicity of the SA55 nasal spray in healthy individuals.
Methods: This phase I, dose-escalation clinical trial combined an open-label design with a randomized, controlled, double-blind design.
Vaccines (Basel)
January 2025
International Centre for Diarrhoeal Disease Research, Bangladesh, 68, Shaheed Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh.
Background: Vaccination has played a crucial role in mitigating the spread of COVID-19 and reducing its severe outcomes. While over 90% of Bangladesh's population has received at least one COVID-19 vaccine dose, the comparative effectiveness of homologous versus heterologous booster strategies, along with the complex interplay of factors within the population, remains understudied. This study aimed to compare antibody responses between these booster approaches.
View Article and Find Full Text PDFVaccines (Basel)
January 2025
School of Medicine, Università Vita-Salute San Raffaele, 20132 Milan, Italy.
Background/objectives: Vaccines have been recognized as one of the most effective public health interventions. However, vaccine-associated anaphylaxis, although rare, is a serious adverse reaction. The incidence of anaphylaxis related to non-COVID-19 vaccines in adults remains underreported.
View Article and Find Full Text PDFVaccines (Basel)
December 2024
Department of Internal Medicine and Oncological Chemotherapy, Medical University of Silesia in Katowice, 40-029 Katowice, Poland.
Background: In Poland, a national hepatitis B (HBV) immunization program was introduced for neonates in 1996, and between 2000 and 2011, those born from 1986 to 1995 were vaccinated. Little is known about vaccination rates among adults born before 1986. This study aimed to determine the frequency of anti-HBs seropositivity rates related to vaccination and past HBV infection in older Poles.
View Article and Find Full Text PDFVaccines (Basel)
December 2024
Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia.
Background/objectives: Adequate knowledge and correct attitudes about the HPV vaccine influence awareness of the importance of preventing HPV-related diseases, which is particularly important for future healthcare professionals. We aim to examine the share of correct answers and the prevalence of different attitudes about the HPV vaccine among active regular students of the Faculty of Medicine in Novi Sad.
Methods: A cross-sectional study was conducted from 1 to 30 November 2023 using a structured survey questionnaire.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!